MBX Biosciences (MBX) Competitors $16.69 -0.06 (-0.36%) As of 10/3/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsSEC FilingsShort InterestTrendsBuy This Stock MBX vs. IDYA, BEAM, CDTX, IRON, AGIO, TVTX, BLTE, OCUL, ETNB, and ARQTShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include IDEAYA Biosciences (IDYA), Beam Therapeutics (BEAM), Cidara Therapeutics (CDTX), Disc Medicine (IRON), Agios Pharmaceuticals (AGIO), Travere Therapeutics (TVTX), Belite Bio (BLTE), Ocular Therapeutix (OCUL), 89BIO (ETNB), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Its Competitors IDEAYA Biosciences Beam Therapeutics Cidara Therapeutics Disc Medicine Agios Pharmaceuticals Travere Therapeutics Belite Bio Ocular Therapeutix 89BIO Arcutis Biotherapeutics MBX Biosciences (NASDAQ:MBX) and IDEAYA Biosciences (NASDAQ:IDYA) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation. Do analysts prefer MBX or IDYA? IDEAYA Biosciences has a consensus price target of $43.36, indicating a potential upside of 56.86%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe IDEAYA Biosciences is more favorable than MBX Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00IDEAYA Biosciences 1 Sell rating(s) 3 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.72 Do institutionals & insiders believe in MBX or IDYA? 98.3% of IDEAYA Biosciences shares are held by institutional investors. 52.2% of MBX Biosciences shares are held by insiders. Comparatively, 2.5% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is MBX or IDYA more profitable? MBX Biosciences' return on equity of -31.33% beat IDEAYA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets MBX BiosciencesN/A -31.33% -29.96% IDEAYA Biosciences N/A -31.42%-29.45% Does the media refer more to MBX or IDYA? In the previous week, IDEAYA Biosciences had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 1 mentions for MBX Biosciences. IDEAYA Biosciences' average media sentiment score of 1.02 beat MBX Biosciences' score of 0.67 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings and valuation, MBX or IDYA? MBX Biosciences has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMBX BiosciencesN/AN/A-$61.92M-$4.54-3.68IDEAYA Biosciences$7M346.05-$274.48M-$3.79-7.29 SummaryIDEAYA Biosciences beats MBX Biosciences on 9 of the 13 factors compared between the two stocks. Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX Biosciences IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$560.68M$2.47B$2.51B$10.58BDividend YieldN/A13.85%2.53%4.69%P/E Ratio-3.6826.1426.7126.70Price / SalesN/A8,723.82119.70131.81Price / CashN/A19.9747.7861.31Price / Book2.173.6736.546.55Net Income-$61.92M-$372.80M$9.75M$277.50M7 Day Performance-4.68%1.29%1.91%2.41%1 Month Performance29.18%3.28%4.15%9.30%1 Year PerformanceN/A14.50%60.37%31.22% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences0.3436 of 5 stars$16.69-0.4%N/AN/A$560.68MN/A-3.68N/AIDYAIDEAYA Biosciences4.3072 of 5 stars$26.83+4.4%$43.36+61.6%-5.5%$2.35B$7M-7.0880Positive NewsAnalyst UpgradeBEAMBeam Therapeutics2.8929 of 5 stars$22.97-0.5%$46.40+102.0%+12.2%$2.32B$63.52M-5.10510Positive NewsCDTXCidara Therapeutics3.9711 of 5 stars$90.50+6.8%$119.43+32.0%+853.2%$2.29BN/A-8.1390Analyst ForecastHigh Trading VolumeIRONDisc Medicine2.0183 of 5 stars$65.55+4.9%$98.30+50.0%+35.2%$2.28BN/A-14.6630Positive NewsAGIOAgios Pharmaceuticals4.3654 of 5 stars$38.93+6.3%$56.00+43.8%-0.1%$2.26B$36.50M3.54390Insider TradeTVTXTravere Therapeutics2.3935 of 5 stars$25.30+2.8%$34.20+35.2%+80.5%$2.26B$233.18M-12.40460Analyst UpgradeBLTEBelite Bio3.0221 of 5 stars$69.980.0%$96.00+37.2%+48.5%$2.23BN/A-45.1510OCULOcular Therapeutix4.0117 of 5 stars$12.53+2.4%$17.83+42.3%+23.6%$2.18B$63.72M-9.79230Trending NewsAnalyst ForecastAnalyst RevisionGap UpETNB89BIO3.136 of 5 stars$14.70flat$25.81+75.6%+107.4%$2.18BN/A-4.0740Options VolumeARQTArcutis Biotherapeutics1.3677 of 5 stars$17.57+5.0%$19.80+12.7%+95.8%$2.11B$196.54M-23.43150Trending NewsInsider Trade Related Companies and Tools Related Companies IDYA Competitors BEAM Competitors CDTX Competitors IRON Competitors AGIO Competitors TVTX Competitors BLTE Competitors OCUL Competitors ETNB Competitors ARQT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBX) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredLost Decade warning – do this nowWith the Magnificent 7 trading at bubble-like valuations, another “Lost Decade” could be looming — but Porter ...Porter & Company | SponsoredThe next biggest bull run in over 50 yearsGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MBX Stock Alerts